当前位置: 首页 > 期刊 > 《上海医药》 > 2019年第18期
编号:13420827
药物性高血压及其防治措施(6)
http://www.100md.com 2019年6月25日 《上海医药》 2019年第18期
     [28] Faruque LI, Lin M, Battistella M, et al. Systematic review of the risk of adverse outcomes associated with vascular endothelial growth factor inhibitors for the treatment of cancer[J]. PLoS One, 2014, 9(7): e101145.

    [29] Tanabe K, Sato Y, Wada J. Endogenous Antiangiogenic Factors in Chronic Kidney Disease: Potential Biomarkers of Progression[J]. Int J Mol Sci, 2018, 19(7). pii: E1859.

    [30] Cameron AC, Touyz RM, Lang NN. Vascular complications of cancer chemotherapy[J]. Can J Cardiol, 2016, 32(7): 852-862.

    [31] Touyz RM, Herrmann SMS, Herrmann J. Vascular toxicities with VEGF inhibitor therapies-focus on hypertension and arterial thrombotic events[J]. J Am Soc Hypertens, 2018, 12(6): 409-425.

    [32] Whelton PK, Carey RM, Aronow WS, et al. 2017 ACC/ AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/ PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Clinical Practice Guidelines[J]. Hypertension, 2018, 71(6): 1269-1324.

    [33] Rizzoni D, De Ciuceis C, Porteri E, et al. Use of antihypertensive drugs in neoplastic patients[J]. High Blood Press Cardiovasc Prev, 2017, 24(2): 127-132.

    [34] Ansari R, Husain K, Rizvi S. Role of Transcription Factors in Steatohepatitis and Hypertension after Ethanol: The Epicenter of Metabolism[J]. Biomolecules, 2016, 6(3). pii: E29., 百拇医药(钱晓珍 李静)
上一页1 2 3 4 5 6